Hexiris Pharma

Hexiris is a French biotechnology company focused on developing next-generation antimitotic therapies for the treatment of solid tumors. The company leverages its expertise in kinesin biology to design highly selective small molecule inhibitors that target specific motor proteins involved in cell division, such as KIF18A and KIF11 (Eg5). By targeting these proteins, Hexiris aims to induce mitotic arrest and apoptosis specifically in cancer cells while minimizing the neurotoxicity often associated with traditional tubulin-targeting agents. Their lead programs are currently in the pre-clinical stage, with a primary focus on high-unmet-need indications including triple-negative breast cancer and ovarian cancer.